OmicsX
innovation INSIGHTS



Global Targeted Protein Degraders 2025

Technologies | Patents | Pipeline | Funding | Deals

Intelligence Updates - April 2025

Disclaimer

At the time of creation of this report, all information present herein was known to be true and accurate, to the best knowledge of creators. HH BioTechnologies accepts no liability whatsoever for any loss or damage resulting from errors, inaccuracies or omissions affecting any part of the publication. All information is provided without warranty, and HH BioTechnologies makes no representation of warranty of any kind as to the accuracy or completeness of any information here to contained.

Contents

Auron Therapeutics, Inc.

Cancer

55 Chapel Street, Suite 102
Newton, MA 02458,
United States

www.aurontx.com
info@aurontx.com
-

Founded: 2018
Employee: 11-50
Ownership: Private

Highlights

- Auron Therapeutics is a clinical stage biotech company developing a pipeline of small molecule TPD therapies, to improve patient outcomes in oncology and inflammatory disease.
- ***Key Technologies*** - Auron has developed AURIGIN™ platform, which uses AI and machine learning to compare cell developmental states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies.
- ***Key Patents*** - 1. Pyridazinon derivatives as kat2 degraders for the treatment of proliferative disorders. - WO2024050078A1. (Dated : 2024-03-07)
- 2. Technologies targeting cell states. -WO2024220843A8. (Dated : 2024-12-19)
- ***Funding*** - In Feb 2025, Auron Therapeutics raised $27 Mn in Series B financing, led by DCVC Bio with additional support from Apollo Health Ventures, Arkin Bio Ventures, BrightEdge (the investment arm of the American Cancer Society), Casdin Capital, Franklin Berger, Mubadala Capital, Polaris Partners and Qiming Venture Partners USA.
- In July 2022, Auron Therapeutics raised $48 Mn in Series A financing, led by DCVC Bio with additional support from Mubadala Capital, Apollo Health Ventures, Arkin Bio Ventures, Polaris Partners, Qiming Venture Partners USA, Eli Lilly and Company, BrightEdge, Franklin Berger and Casdin Capital.
- In Jan 2021, Auron Therapeutics received $12.75 Mn in Seed financing, led by Polaris Partners, Arkin Bio Ventures and Qiming Venture Partners USA with additional support from Eli Lilly and Company, BrightEdge (the investment arm of the American Cancer Society), Casdin Capital and Franklin Berger.

Targed Protein Dregrader Pipeline

Name	Target	Phase	Indication	NCT Number	Degrader Modality
AUTX-703	KAT2A/KAT2B	I IND	Acute Myeloid Leukemia Small Cell Lung Cancer Neuroendocrine Prostate Cancer	NCT06846606	Hetrobifunctional
Undisclosed	KAT2A/KAT2B	Preclinical	Inflammatory Diseases		Hetrobifunctional

Drug Descriptions

- AUTX-703 is a first-in-class, oral KAT2A/B degrader, which is developed for the treatment of both hematologic malignancies and solid tumors.
- KAT2A/B are lysine acetyltransferases that epigenetically reprogram cells to a more proliferative and plastic cell state to drive disease: thus KAT2A/B can be a key driver of cell plasticity and disease.

Corporate Profile

Kate Yen, *Chief Executive Officer* *kate.yen@aurontx.com* Linked in profile

David Millan, *Chief Scientific Officer* Linked in profile

Baylink Biosciences

Cancer

2460 Embarcadero Way
Palo Alto, CA 94303
United States

www.baylinkbio.com
info@baylinkbio.com
-

Founded: 2025
Employee: 11-50
Ownership: Subsidiary

Highlights

- ★ Baylink Biosciences is a preclinical stage biotech company building an innovative portfolio of Degrader Antibody Conjugates, Antibody Drug Conjugates delivering traditional chemotherapy, and Dual Payload ADCs targeting cancer.
- ★ Baylink Biosciences is a subsidiary of Asieris Pharmaceuticals (688176.SH), focused on developing a linker platform for antibody drug conjugates (ADCs), to expand the therapeutic window.
- ★ ***Key Technologies*** - Baylink has created a panel of linker-payloads that enhance the delivery of hydrophobic compounds with high drug-to-antibody ratios (DAR) and stability. Also, Baylink is developing innovative payloads beyond TOP1i and MMAE payloads.
- ★ Baylink is advancing several product candidates based on this platform to the clinic that represent first-in-class or best-in-class ADC therapeutics.

Targed Protein Dregrader Pipeline

Name	Target	Phase	Indication	Degrader Modality
BLB-201	Undisclosed	Preclinical	Acute Myeloid Leukemia	Antibody Degrader Conjugate
BLB-202	Her2	Discovery	Breast Cancer	Antibody Degrader Conjugate

Drug Descriptions

- ★ BLB-101 is a topoisomerase-inhibitor-based anti-CLDN6/9 antibody-drug conjugate featuring a proprietary hydrophilic linker.

Corporate Profile

Alice Chen, *Co-founder & CSO* — Linked in profile

Darren Buchwald, *Chief Operating Officer* — Linked in profile

EpiTET Therapeutics, Inc.

Diversified

470 James Street #007
New Haven, CT 06513,
United States

www.epitettx.com
erika.smith@epitettx.com
+1 203.444.6642

Founded: 2024
Employee: 11-50
Ownership: Private

Highlights

- EpiTET is pioneering a precision medicine approach to chronic inflammatory diseases and cancer through its proprietary molecular glue degrader technology. The company is focused on selectively eliminating disease-driving macrophages by targeting novel, epigenetic regulators of inflammation.
- ***Key Technologies*** - EpiTET's key scientific innovations centers around Ten-eleven translocation 3 (TET3), an enzyme involved in epigenetic regulation through DNA demethylation. TET3 is found to be significantly overexpressed in macrophages within endometriotic lesions, where it plays a pivotal role in sustaining chronic inflammation. These TET3-overexpressing macrophages not only drive disease progression in endometriosis but are also implicated in shaping an immunosuppressive tumor microenvironment in certain cancers.
- EpiTET's molecular glue degrader platform is designed to induce the selective degradation of TET3, thereby removing pathogenic macrophages and breaking the cycle of chronic inflammation. Unlike conventional inhibitors, molecular glues hijack the cell's natural protein degradation machinery, offering superior target specificity, improved durability of response, and reduced off-target effects.
- Going beyond target degradation, EpiTET's precision molecular phenotyping approach enables the identification of patient subsets most likely to benefit from macrophage-targeted therapy. This dual strategy—precision phenotyping + novel molecular glues—allows EpiTET to address two major challenges in medicine:
- 1) Treating endometriosis-associated inflammation at its root cause.
- 2)Overcoming immunotherapy resistance in cancer by reprogramming the tumor microenvironment and eliminating inflammatory macrophages in selected patient populations.
- By combining deep molecular insights with targeted degradation technology, EpiTET is advancing a transformative therapeutic platform with the potential to reshape the treatment landscape for chronic inflammatory diseases and difficult-to-treat cancers.

Corporate Profile

Erika Smith, *Chief Executive Officer* *erika.smith@epitettx.com* Linked in profile

PrimeLink BioTherapeutics (Shenzhen) Co., Ltd.

Cancer

Building 4, Suhua Science Park , No.208 Tongyuan Road, Suzhou Industrial Park, China

www.primelinkbio.com
hr@primelinkbio.com
+86 512 62652000

Founded: 2021
Employee: 2-10
Ownership: Private

Highlights

- PrimeLink Bio is a preclinical stage biotech company developing next generation Antibody Drug Conjugates (ADCs) based first-in-class & best-in-class products.
- PrimeLink has developed ***PrimeLink HydramiX ADC Technology Platform*** - a Lego's modular toolbox-style technology platform, which is compatible with a wide range of current technologies, and is capable of conjugating various payloads with diverse mechanisms of action (MOAs), regardless of their hydrophobicity. The platform also enables precise control over the drug-to-antibody ratio (DAR), ensuring optimal efficacy. HydramiX ADC exhibits excellent stability in circulation, with favorable pharmacokinetic profiles and outstanding tolerability.
- PrimeLink has expanded its ADC portfolio to include innovative formats such as bispecific ADCs, immune-stimulating antibody conjugates (ISACs), protein-degrader antibody conjugates (DACs), dual-drug ADCs and antibody-oligonucleotide conjugates (AOCs).
- In Dec 2022, PrimeLink Bio has raised a RMB 150 million in angel funding round from Vertex Ventures, Fosun, Kaitai Capital, etc.

Targed Protein Dregrader Pipeline

Name	Target	Phase	Indication	Degrader Modality
PLB-007	Undisclosed	Discovery	Solid Tumor	Degrader Antibody Conjugate

Corporate Profile

Mao Yin, *Chief Scientific Officer and Founder* Linked in profile

Protier Biotech, Inc.

Cancer

(05554) 235, 2nd floor, 240 Olympic-ro, Songpa-gu, Seoul, Republic of Korea

www.protierbiotech.com
contact@protierbiotech.com
-

Founded: 2022
Employee: 11-50
Ownership: Private

Highlights

- Protier Biotech is focusing on developing molecular adhesion degraders using the ubiquitin-proteasome degradation system and is also develops DAC (Degrader-Antibody Conjugate) that uses molecular glue as ADC payload.
- ***Key Technologies*** - **PROTIER-Glue** Platform - Molecular adhesives are a novel therapeutic modality that induce new protein-protein interactions to degrade disease-causing and undruggable proteins. Compared to PROTACs, they have a simpler structure, smaller size, better pharmacological properties, higher membrane permeability, improved cell uptake, and superior blood-brain barrier (BBB) penetration, making them highly promising.

Targed Protein Dregrader Pipeline

Name	Target	Phase	Indication	Degrader Modality
PTB600	GSPT1	Discovery	Haematological malignancies Solid Tumors	Degrader-Antibody Conjugate
PTB500	Undisclosed	Discovery	Ovarian Cancer	Molecular Glue

Corporate Profile

Kim Hyun-tae, *Chief Executive Officer* Linked in profile

Ji Hyun Lee, *Chief Scientific Officer* Linked in profile

SPIMA Therapeutics Inc.

Diversified

80, avenue Augustin Fliche
34295 Montpellier,
France

www.spima-therapeutics.com
haitham.ayad@spima-therapeutics.com
-

Founded: 2024
Employee: 1-10
Ownership: Private

Highlights

- SPIMA Therapeutics is a preclinical stage biotech company developing peptide-based immunotherapies to target protein-protein interactions.
- SPIMA Therapeutics is a spin-off from the University of Montpellier, France and was co-founded by Prof. Christian Jorgensen, Prof. Jean Martinez, Dr. Florence Apparailly, Dr. Muriel Amblard and Landmark BioVentures AG (LBV).
- Company's lead program SPM001 is a stapled peptide designed to block the Myddosome complex with exceptional pharmacological properties and the potential to address severe immunological disorders and aggressive cancers characterized by MyD88 mutations.
- ***Key Technologies*** - SPIMA's technology stabilizes peptides in their bioactive α-helical conformation using a chemical brace, enhancing their stability, cell permeability and suitability for targeting intracellular protein-protein interactions—making them ideal candidates for Peptide PROTAC development.
- ***Funding*** - SPIMA Therapeutics is Landmark Bioventures backed company.

Targed Protein Dregrader Pipeline

Name	Target	Phase	Indication	Degrader Modality
SPM002	Undisclosed	Preclinical	Oncology	PROTAC Peptide

Corporate Profile

Mohamed Haitham Ayad, *Chief Executive Officer* *haitham.ayad@spima-therapeutics.com* Linked profile

Zaki Sellam, *Chairman* Linked profile

TARGETED PROTEIN DEGRADATION (TPD) FUNDING & DEALS UPDATES - APRIL 2025

Private Financing Updates - Feb / April 2025

No.	Company Name	Country	Funding Amount	Funding Round	Month / Year	Key Investors in the Round
1.	Prazer Therapeutics	*United Kingdom*	29 billion won	Series B	April-25	Johnson & Johnson Innovation, K2 Investment, Mirae Asset Capital, Quad Asset Management, STIC Ventures, Company K Partners, Kiwoom Investment, and Smilegate Investment.
2.	Solu Therapeutics, Inc	*United States*	$ 41 Mn USD	Series A	April-25	Eli Lilly and Company, Biovision Ventures, Pappas Capital, Hengdian Group Capital (HgC), The Leukemia & Lymphoma Society Therapy Acceleration Program®, Solu investors Longwood Fund, DCVC Bio, Santé Ventures, Astellas Venture Management, and Alexandria Venture Investments.
3.	Insilico Medicine, Inc.	*United States*	$110 Mn USD	Series E	Mar-25	Value Partners Group (HKG:0806)
4.	TRIMTECH Therapeutics Limited	*United Kingdom*	$31 Mn USD (£25 Mn)	Seed Funding	Mar-25	Cambridge Innovation Capital (CIC), SV Health Investors' Dementia Discovery Fund (DDF), M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures and Start Codon.
5.	Captor Therapeutics	*Poland*	€2.5 Mn	Grant	Feb-25	European Innovation Council (EIC) Accelerator

Targeted Protein Degradation Drug Development Companies
Major TPD Linked Business Deals & Collaborations in Feb / April 2025

No.	TPD Drug Developer	Partner Company	Deal Size	Month	Description
1.	Nurix Therapeutics, Inc.	Sanofi SA	$465 Mn USD	April 2025	Nurix Therapeutics out-licensed Sanofi, an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases and is distinct from the previously disclosed STAT6 degrader program. Nurix is eligible for an additional $465 Mn in development, regulatory and commercial milestones for this program as well as potential future royalties and retains an option to co-develop and co-promote in the United States with the parties splitting U.S. profits and losses.
2.	Gluetacs Therapeutics	Fudan University		March 2025	Gluetacs Therapeutics and Fudan University's Sun Tao/Jiang Chen team develop a PROTAC-loaded nanocapsule targeting BRD4 degradation to break through the radiochemotherapy resistance bottleneck in glioblastoma.
3.	GV20 Therapeutics	Mitsubishi Tanabe Pharma Corporation		March 2025	GV20 Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC) collaborate to discovered novel tumor antigen targets through GV20's proprietary STEAD AI platform. Under the terms, GV20 will receive an upfront payment and is eligible for milestone payments.
4.	Magnet Biomedicine	Eli Lilly	$1.25 billion USD	Feb-25	Magnet Biomedicine signed license agreement with Eli Lilly & Company to discover, develop and commercialize molecular glue therapeutics in oncology. The collaboration will leverage Magnet's TrueGlue™ discovery platform to identify molecular glues capable of inducing protein proximity and cooperativity, enabling novel mechanisms of action to address difficult-to-drug targets spanning multiple diseases with unmet medical need. Under the terms, Magnet will receive upfront, near-term payments and an equity investment of up to $40 Mn and is also eligible to receive a total of more than $1.25 billion in milestones upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales.
5.	Photys Therapeutics	Hangzhou Polymed Biopharmaceuticals, Inc	Undisclosed	Feb-25	Photys Therapeutics enters into an exclusive in-license with Hangzhou Polymed Biopharmaceuticals, Inc., for HPB-143 a phase 1-ready and potentially best-in-class IRAK4 degrader. Under the terms of the agreement, Polymed has granted Photys an exclusive global (ex-greater China and Southeast Asia) license to develop, manufacture, and commercialize HPB-143, which will be renamed to PHT-776. Financial terms of the agreement were not disclosed.
6.	Y Biologics, Inc.	Ubix Therapeutics	Undisclosed	Feb-25	Y-Biologics, an antibody drug discovery platform company, collaborate with Ubix Therapeutics, to codevelop degrader antibody conjugate (DAC) drugs, that combine antibodies discovered by Y-Biologics with Ubix Therapeutics' TPD technology. Further, financial details remains undisclosed.
7.	HealZen Therapeutics	Johnson & Johnson		Jan 2025	HealZen Therapeutics and Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM), jointly announced today it has entered into a global license agreement with Johnson & Johnson to develop potential best-in-class BTK degraders for the treatment of multiple diseases.
8.	LE..... Pharma A/S	G..... Sciences, Inc	$1.7 Billion USD	Jan 2025	LEO Pharma A/S and Gilead Sciences, entered into a strategic partnership to accelerate the development and commercialization of LEO Pharma's oral STAT6 programs for the potential treatment of inflammatory diseases. Under this partnership, Gilead will acquire LEO Pharma's comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. LEO Pharma may receive up to $1.7B, including a $250 Mn upfront and tiered royalties (high single to mid-teens) on oral STAT6 sales.

Targeted Protein Degradation Drug Development Companies
TPD Linked Mergers and Acquisition (M&A) in 2025

No.	TPD Drug Developer	Partner Company	Deal Size	Month	Description
1.	Vividion Therapeutics	Tavros Therapeutics	Acquisition	Jan-25	In Jan 2025, Vividion Therapeutics acquired Tavros Therapeutics to expand functional genomics capabilities and boost drug discovery platform. Vividion and Tavros have been working together for the past two years under a strategic collaboration to discover and develop novel precision therapeutics capable of addressing cancer-causing proteins that have eluded traditional small molecule drugs.
2.	Salarius Pharmaceuticals, Inc	Decoy Therapeutics	Merger	Jan-25	In Jan 2025 Salarius Pharmaceuticals, Inc and Decoy Therapeutics will merge with a wholly-owned subsidiary of Salarius Pharmaceuticals, subject to the closing conditions set forth in the definitive agreement. The newly formed company will be named Decoy Therapeutics.
3.	Ikena Oncology, Inc.	Inmagene Biopharmaceuticals	Merger	Dec-24	In Dec 2024, Ikena Oncology, Inc. and Inmagene Biopharmaceuticals have entered into a definitive merger agreement. The combined company plans to operate under the name “ImageneBio, Inc.” (“ImageneBio”) and trade on NASDAQ under the ticker “IMA”.

TARGETED PROTEIN DEGRADATION (TPD) RESEARCH PIPELINE UPDATES - APRIL 2025

New TPD Molecules Addition - Feb / March 2025

No.	Company Name	Country	Molecule Name	Target	Phase	Indication	Degrader Modality
1.	Amphista Therapeutics Limited	United Kingdom	Undisclosed	SMARCA2	Discovery	Non-Small Cell Lung Cancer	Molecular Glue
2.	BeiGene (Beijing) Co., Ltd	China	BGB-45035	IRAK4	I	Immunology & inflammation	cDAC (Chimeric Degrader)
3.	Blueprint Medicines Corporation	United States	Undisclosed	CDK4	Discovery	Breast Cancer	Bifunctional Degrader
4.	Bristol Myers Squibb	United States	CC2000199 / CC-199	Androgen Receptor	Preclincal	Prostate Cancer (mCRPC)	Hetrobifunctional Degrader
5.	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China	Undisclosed	Androgen Receptor (AR/ARv7)	Discovery	Oncology	Heterobifunctional Degrader
			TQB3019	BTK	Preclincal	B-cell malignancies	Hetrobifunctional Degrader
6.	Evo.... Bio..... Co., Ltd.	China					Heterobifunctional
7.	Ge.....h, Inc.	United States					Heterobifunctional
8.	Gl..... Therapeutics	China					Molecular Glue
							Molecular Glue
							Molecular Glue
9.	Heal..... Co., Ltd.	China					Molecular Glue
10.	Hua..... Co., Ltd.	China					Molecular Glue
11.	Inno....., Inc.	South Korea					Molecular Glue
12.	Ka....	Belgium					Heterobifunctional
13.	L..... Therapeutics, Inc.	United States					LYTACs (lysosome-targeting chimeras)
							LYTACs (lysosome-targeting chimeras)
							LYTACs (lysosome-targeting chimeras)
							LYTACs (lysosome-targeting chimeras)
							LYTACs (lysosome-targeting chimeras)
14.	Novartis International AG	Switzerland					Molecular Glue
15.	Nurix, Inc.	United States	NRX-0305	BRAF	Discovery	Solid tumors	Heterobifunctional
			Undisclosed	Aurora A	Discovery	Solid tumors	Molecular Glue

EVENT COVERAGE -
TARGETED PROTEIN DEGRADATION @ AACR 2025

AACR Annual Meeting 2025 - Poster Presentation - Drug Development

No.	Company Name	Country	Molecule Name	Target	Phase	Indication	Degrader Modality	Further Details
1.	Arvinas Operations, Inc.	United States	ARV-393	BCL6	I	Diffuse Large B-cell lymphoma (DLBCL)	PROTAC	AACR 2025 Link
2.	Bristol Myers Squibb	United States	CC2000199 / CC-199	Androgen Receptor	Preclincal	Prostate Cancer (mCRPC)	Hetrobifunctional Degrader	AACR 2025 Link
3.	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China	TQB3019	BTK	Preclincal	B-cell Malignancies	Hetrobifunctional Degrader	AACR 2025 Link
4.	Cyrus Therapeutics	South Korea	CYRS1542	GSPT1	Discovery	Neuroendocrine Cancer	Moleculer Glue	AACR 2025 Link
5.	Ensem Therapeutics	United States	ETX-636	PI3Kα	Preclincal	Solid Tumors	Inhibitor / Degrader	AACR 2025 Link
6.	Erasca, Inc.,	United States	ERAS-0015	panRAS	IND	Solid Tumors	Moleculer Glue	AACR 2025 Link
7.	Foghorn Therapeutics	United Kingdom	Undisclosed	CBP	Discovery	Solid Tumors	Hetrobifunctional Degrader	AACR 2025 Link
8.	Gan & Lee Pharmaceuticals	China	GLR203101	SMAR-CA2	Discovery	Oncology	Hetrobifunctional Degrader	AACR 2025 Link
9.	GenFleet Therapeutics	China	GFH276	panRAS	Discovery	Soild Tumors	Moleculer Glue	AACR 2025 Link
10.	Haisco Pharma-ceutical Group Co Ltd.	China	HSK47977	BCL6	Preclincal	Diffuse large B-cell lymphoma	Hetrobifunctional Degrader	AACR 2025 Link
11.	Handok Inc. & BNJ Biopharma Inc	South Korea	HDBNJ3049	EGFR	Discovery	Non Small Cell Lung Cancer	PROTAC	AACR 2025 Link
12.	HealZen Therapeutics Co., Ltd	China	HZ-S109	HPK1	IND	Solid Tumors	Hetrobifunctional Degrader	AACR 2025 Link
			HZ-V068	RAS	Discovery	Pancreatic Ductal Adeno-carcinoma	Moleculer Glue	AACR 2025 Link
						Colorectal Cancer		
13.	Huadong Medicine Co., Ltd.	China	Undisclosed	GSPT1	Discovery	Solid Tumors	Moleculer Glue	AACR 2025 Link
14.	InnoPharmaScreen	South Korea	IPS-06061	KRAS G12D	Discovery	Solid Tumors	Moleculer Glue	AACR 2025 Link
15.	Leadingtac Pharmaceutical (Shaoxing) Co., Ltd		LT-010366	KRAS G12D	Preclincal	Pancreatic Ductal Adenocarcinoma	Hetrobifunctional Degrader	AACR 2025 Link
						Colorectal Cancer		
16.	Nurix Therapeutics	United States	NRX-0305	BRAF	Preclincal	Solid Tumors	Hetrobifunctional Degrader	AACR 2025 Link
17.	Open Source Therapeutics	China	OST08267	PDE3A-SLFN12	Preclincal	Gastrointestinal stromal tumor	Moleculer Glue	AACR 2025 Link
18.	Plexium	United States	PLX-61639	SMARCA2	Preclincal	SMARCA4^{MUT} Solid Tumors	Monovalent Degrader	AACR 2025 Link

No.	Company Name	Country	Molecule Name	Target	Phase	Indication	Degrader Modality	Further Details
20.	Prelude Therapeutics Inc	United States	PRT3789	SMAR-CA2/4	I	Solid Tumors	Hetrobifunctional Degrader	AACR 2025 Link
			Undisclosed	KAT6A	Preclincal	Solid Tumors	Hetrobifunctional Degrader	AACR 2025 Link
21.	Prospect Therapeutics	China	Undisclosed	GSPT1	Discovery	Solid Tumors	Moleculer Glue	AACR 2025 Link
22.	Pin Therapeutics	South Korea	PIN5018	CK1α	Preclincal	Colorectal Cancer	Hetrobifunctional Degrader	AACR 2025 Link
23.	Risen Pharmaceuticals Private Ltd.	China	RP04340	KRAS G12	Preclincal	Solid Tumors	PROTAC	AACR 2025 Link
24.	SEED Therapeutics Inc.	United States	Undisclosed	KRAS G12D, Androgen Receptor	Discovery	Prostate Cancer (mCRPC)	dual-PROTAC	AACR 2025 Link
25.	Shanghai Hengrui Pharmaceutical CO., LTD.	China	SHR3591	Androgen Receptor	I/II	Prostate Cancer (mCRPC)	PROTAC	AACR 2025 Link
26.	Shenzhen TargetRx, Inc.	China	TGRX-3544	KIT	Preclincal	Gastrointestinal Stroma Tumors (GIST)	Hetrobifunctional Degrader	AACR 2025 Link
						Systemic Mastocytosis		
27.	Therapex	South Korea	TRX-214-1002	GSPT1	Preclinical	Acute Myeloid Leukemia	Degrader Antibody Conjugate	AACR 2025 Link
28.	Ubix Therapeutics Co., Ltd	South Korea	Undisclosed	SHP2	Preclincal	Solid Tumors	Hetrobifunctional Degrader	AACR 2025 Link

AACR 2025 - Poster Presentation - TPD Screening Technologies by CROs

No.	Company Name	Country	Title Name	Further Details
1.	ICE Bioscience, Inc.	China	A comprehensive platform for the screening and assessment of IRAK4-targeting PROTACs.	AACR 2025 Link
			A comprehensive screening and evaluation platform for KRAS molecular glue, covering studies from in vitro to in vivo. The platform includes a series of assays at both the biochemical and cellular levels.	AACR 2025 Link
2.	PhoreMost Limited	United Kingdom	Cell-based screening platforms, SITESEEKER® and GlueSEEKER™	AACR 2025 Link
3.	Eurofins Discovery	Taiwan	OncoPanel® platform would further demonstrate the therapeutic potential and selectivity of AR degrader.	AACR 2025 Link
4.	Selvita Inc	United States	Development of an integrated multi-modal platform for comprehensive analysis of targeted protein degraders in a drug discovery setting.	AACR 2025 Link
5.	Pelago Bioscience AB	Sweeden	The Cellular Thermal Shift Assay (CETSA) is a powerful technology for identifying the interactions between compounds and their cognate protein targets.	AACR 2025 Link
6.	Sygnature Discovery	United Kingdom	Drug target ID and binding site mapping in complex cellular environments using LiP-MS.	AACR 2025 Link

Contact Us

reports@omicsx.com
2760 Link Road, Industrial Area,
AGRA 282006, INDIA

Phone : (+91) 562 2970444

Mobile : (+91) 9760 241 412

Website : www.omicsx.com